Stem Cell Transplant or Cellular Therapy - Allogeneic

Allogeneic

AML/MDS/ALL

Severe Aplastic Anemia

Multiple Diseases

IRB# 10146
Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate-2 and high risk myelodysplastic syndrome.

IRB# 16943
BMT CTN phase II study of ATG-based conditioning regimens for haploidential and cord blood transplants.

IRB# 16982
Donor T-Cell infusion for adults with recurrent minimal residual disease post HSCT.

IRB# 11960
Long Term Follow Up Study to monitor all patients exposed to CD19 directed CAR-T Cells.

IRB# 18301
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients.

IRB# 17622
Tests the drug Glutertinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.

IRB# 16189
Phase 1/phase 2 study of ProTmune ex vivo mobilized peripheral blood cells.

IRB# 19142
Safety and Efficacy study of ATIR101 Compared to Post-transplant Cyclophosphamide for the prevention of GVHD in a haploidential transplant (HATCY).

IRB# 18142
Safety and Efficacy study of ATIR101 Compared to Post-transplant Cyclophosphamide for the prevention of GVHD in a haploidential transplant (HATCY).

IRB# 16995
Tests the drug PRO 140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.

IRB# 10146
Tests the drug Glutertinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.

MDS Only

AML Only

AML/MDS Only

AML/MDS/ALL

MDS Only

AML Only

AML/MDS Only

MDS

Only

2/11/2019

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment

In Development

Enrollment on Hold

AML/MDS/ALL

AML/MDS/ALL

AML/MDS/ALL

AML/MDS/ALL

AML/MDS/ALL

AML/MDS/ALL

AML/MDS/ALL

AML/MDS/ALL

AML/MDS/ALL